TrialBlood advances2020

Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis.

Ariela Noy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.